CellMidi develops PLUS CAR T technology that utilizes gene-edited immune cells to enhance CAR T cell therapy outcomes in solid tumors. This approach targets immune suppression within the tumor microenvironment, providing a cost-effective treatment option for patients with previously untreatable cancers.
Funding
Funding not disclosed
Founders
Product
Problem
Solid tumors often create immunosuppressive microenvironments that limit the effectiveness of CAR T-cell therapies. Current CAR T-cell treatments face challenges in penetrating and persisting within these tumors, resulting in suboptimal outcomes for patients with previously untreatable cancers.
Solution
CellMidi is developing PLUS CAR T technology, a gene-edited immune cell therapy designed to overcome immune suppression within solid tumor microenvironments. This next-generation CAR T approach enhances the ability of CAR T-cells to infiltrate tumors, resist immunosuppressive signals, and effectively target and eliminate cancer cells. By modifying the CAR T-cells' genetic makeup, CellMidi aims to improve their persistence and anti-tumor activity, leading to more durable responses in patients with advanced solid tumors. The PLUS CAR T platform offers a potential cost-effective treatment option by improving the efficacy of CAR T-cell therapy, potentially reducing the need for additional interventions.
Target Audience
The primary target audience includes patients with advanced solid tumors who have not responded to conventional treatments, as well as oncologists and hematologists specializing in cell and gene therapies.
Features
- Gene-edited CAR T-cells engineered for enhanced tumor infiltration
- Modified immune cells designed to resist immunosuppressive signals within the tumor microenvironment
- Enhanced CAR T-cell persistence for sustained anti-tumor activity
- Targeted elimination of cancer cells within solid tumors